[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637715":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":10,"centralContacts":36,"locations":42,"responsibleParty":64,"collaborators":10,"id":68,"slug":10,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Sohag University","OTHER",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Euthyroid group",null,"Participants whom thyroid function tests are normal and screened for Metabolic dysfunction - associated Steatoic liver disease (MASLD).",[13,14],"Diagnostic Test: FibroScan","Diagnostic Test: Thyroid Function Assessment",{"label":16,"type":10,"description":17,"interventionNames":18},"Case group-1","Patients with overt primary hypothyroidism (High TSH and low FT4, FT3) that screening for Metabolic dysfunction - associated Steatoic liver disease (MASLD).",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Case group-2","Patients with sub clinical hypothyroidism (High TSH and normal FT4, FT3) and screened for Metabolic dysfunction - associated Steatoic liver disease (MASLD).",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Case group-3","Patients with positive thyroid auto-antibodies (normal TSH, normal FT4, normal FT3, Positive TPo antibody or positive thyroglobin antibody) screened for Metabolic dysfunction - associated Steatoic liver disease (MASLD).",[13,14],[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"DIAGNOSTIC_TEST","FibroScan","Participants will undergo assessment of thyroid function status and evaluation for metabolic dysfunction-associated steatotic liver disease (MASLD) using laboratory investigations, abdominal ultrasonography, and vibration-controlled transient elastography (FibroScan).",[16,20,24,9],{"type":29,"name":34,"description":31,"armGroupLabels":35,"otherNames":10},"Thyroid Function Assessment",[16,20,24,9],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Islam K Fathy, MSc","CONTACT","00201011456295","islam.ali2@med.sohag.edu.eg",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Sohag","Sohag Governorate","82511","Egypt",{"type":50,"coordinates":51},"Point",[52,53],31.69478,26.55695,{"lat":53,"lon":52},[56,57,60,62],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},{"name":58,"role":59,"phone":10,"phoneExt":10,"email":10},"Nayel A Zaki, MD","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":10,"phoneExt":10,"email":10},"Amal K Ahmed, MD",{"name":63,"role":59,"phone":10,"phoneExt":10,"email":10},"Ahmed N Nour Eldin, MD",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Islam Khaled Fathy","Assistant lecturer of Internal Medicine, Sohag University, Egypt.","100637715",false,"NCT07603817","Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease in Non-Diabetic Patients","Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease (MASLD) in Non-Diabetic Patients","Inclusion Criteria:\n\n* Patients aged ≥18years old who will be:\n* Diagnosed with primary hypothyroidism (overt or sub clinical hypothyroidism) within 3 months with or without levothyroxine treatment.\n* Patients with positive antibody (positive TPO antibody or positive Thyroglobin antibody) irrespective of thyroid status\n* Metabolic dysfunction-associated steatotic liver disease (MASLD) assessment by ultrasound and Fibro-scan.\n\nExclusion Criteria:\n\n* Diabetic patients according to American Diabetes Association (ADA) Criteria.\n* Excessive Alcohol consumption (\\> 30 gm\u002F day in men, 20 gm \u002Fday in women.\n* Body mass index (BMI) index \\>40 kg\u002Fm2\n* Other causes of chronic hepatic steatosis \\[e.g., positive hepatitis B virus (HBV), positive hepatitis C virus (HCV)), autoimmune disease, Wilson disease, drugs\\].\n* Patients use of drugs known to cause hepatic steatosis (e.g., amiodarone, valproate, tamoxifen, methotrexate, steroids).\n* Treatment with drugs that influence liver fat, as thiazolidinediones, α-glucosidase inhibitors, sodium-glucose -transporter 2 (SGLT2) inhibitors or any glucagon-like peptide-1 receptor agonists during the previous 3 months.\n* Detection of biliary duct obstruction based on imaging studies.\n* Evidence of cirrhosis \\[on basis of ultrasonography and magnetic resonance imaging (MRI )\\] or hepatocellular carcinoma \\[evidence on triphasic Computed Tomography (CT) or MRI\\].\n* Presence of any systemic disease that commonly cause liver disease.\n* Severe hepatic injury and\u002For significant abnormal liver function defined as aspartate aminotransferase \\>5× upper limit of normal (ULN) and\u002For alanine aminotransferase \\>5× ULN or elevated total bilirubin \\> 2 mg\u002Fdl.\n* Pregnant women.\n* Patients with active malignancy.\n* History of bariatric surgery or ongoing weight-loss diet (hypocaloric diet) or use of weight-loss agents unless the diet or treatment has been stopped at least 3 months before screening and that the patient has had a stable body weight (+\u002F- 3 kg) during the 3 months before screening.","ALL","18 Years",{"count":77,"type":78},200,"ESTIMATED","OBSERVATIONAL","This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in Hashimoto-thyroiditis vs Euthyroid controls in non-diabetic patients.",[82,83,84,85,86],"Overt","Sub-clinical","Primary Hypothyroidism","Metabolic Dysfunction-Associated Steatoic Liver Disease","Non-Diabetic Patients","2026-05-30",{"date":89,"type":90},"2026-06-02","ACTUAL",{"date":92,"type":90},"2026-03-01",{"date":94,"type":78},"2027-03-01",{"name":5,"class":6},1]